Bod Science (ASX:BOD) Growth Rank: 0 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:BOD Bod Science Ltd ASX:BOD
12 GF Score
Price A$0.02
GF Value A$0.04
! 3 Warning Signs
View Full Analysis

What is Bod Science Growth Rank?

Bod Science has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ASX:BOD
12GF Score
Bod Science Ltd ASX:BOD
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bod Science (ASX:BOD) Overvalued in 2026?

Based on GuruFocus' analysis, Bod Science stock appears to be undervalued. The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.

Key valuation signals for ASX:BOD:

  • Growth Rank: 0
  • GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bod Science Business Description

Address C/- Rodgers Reidy, 210 Clarence Street, Level 12, Sydney, NSW, AUS, 2000
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score

Get the complete analysis for ASX:BOD

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.02
Price
A$0.04
GF Value